Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 423 participants.

Also called NCT04610892

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 423 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04610892
  • EudraCT 2020-000840-75
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Czechia, Hungary, Italy, Japan, Netherlands, Poland, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04610892. Randomized; quadruple masking; primary purpose treatment. Start 2020-11-04 (actual); primary completion 2023-11-08 (actual). Results posted on 2025-02-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction
Acronym
GOLDILOX
Condition
Coronary Heart Disease (CHD)
Intervention (Biological)
MEDI6570
Intervention (Biological)
Placebo
Lead sponsor
AstraZeneca (class: industry)
Collaborator
The TIMI Study Group (class: other)

Record details

Record id
cardio:ct-nct04610892
Content hash
fbddec3c04df1446f52704fde48d70a2b79e408a12ac239beefc10f4deb78967